Your new post is loading...
(Reuters) - Worldwide spending on cancer medicines reached $100 billion in 2014, an increase of 10.3 percent from 2013 and up from $75 billion five years earlier, according to IMS Health's Global Oncology...
Via Krishan Maggon
|
Rescooped by Gilbert C FAURE from Cancer Vaccines Collection |
Scoop.it!
Via Krishan Maggon
The US has 42% of the global cancer market. In the EU, Germany, France, UK, Italy and Spain are the top 5.
Medicines that target a specific protein or genetic mutation, as opposed to chemotherapies, now account for almost half of total U.S. cancer drug spending, IMS.
Forty-five new cancer drugs were launched between 2010 and 2014. But patients in no country had access in 2014 to all 37 launched between 2009 and 2013. The broadest access was seen in the United States, Germany and Britain, while fewer than half the new drugs were available in South Korea, Spain or Japan, the report said.
Five-year survival rates for many cancers are rising, the report found, with new immunotherapies, such as Merck's Keytruda and Bristol's Opdivo, holding the promise of improved survival with fewer side effects.
The US has 42% of the global cancer market. In the EU, Germany, France, UK, Italy and Spain are the top 5.
Medicines that target a specific protein or genetic mutation, as opposed to chemotherapies, now account for almost half of total U.S. cancer drug spending, IMS.
Forty-five new cancer drugs were launched between 2010 and 2014. But patients in no country had access in 2014 to all 37 launched between 2009 and 2013. The broadest access was seen in the United States, Germany and Britain, while fewer than half the new drugs were available in South Korea, Spain or Japan, the report said.
Five-year survival rates for many cancers are rising, the report found, with new immunotherapies, such as Merck's Keytruda and Bristol's Opdivo, holding the promise of improved survival with fewer side effects.